Santen Pharmaceutical Co., Ltd. (USD) Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Santen Pharmaceutical Co., Ltd. (USD) Active

Grand Front Osaka Tower A, Osaka, JP, 530-8552

Stock Price USD

Price Change

Last Dividend USD

SNPHF's stock peer is GRFS (Grifols, S.A.)

SNPHF's stock peer is OPHLY (Ono Pharmaceutical Co., Ltd.)

Healthcare Drug Manufacturers - General

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2026-03-31		0.13	2.34 %	Semi-Annual
2025-09-30		0.13	2.32 %	Semi-Annual
2025-03-31	2025-06-25	0.13	2.31 %	Semi-Annual
2024-09-30	2024-11-29	0.12	1.94 %	Semi-Annual
2024-03-31	2024-06-26	0.11	2.32 %	Semi-Annual
2023-09-30	2023-11-30	0.11	2.43 %	Semi-Annual
2023-03-31	2023-06-28	0.12	2.67 %	Semi-Annual
2022-09-30	2022-11-30	0.11	3.52 %	Semi-Annual
2022-03-31	2022-06-27	0.13	2.40 %	Semi-Annual
2021-09-30	2021-11-30	0.14	1.87 %	Semi-Annual
2021-03-31	2021-06-28	0.13	1.86 %	Semi-Annual
2020-09-30	2020-11-30	0.13	1.31 %	Semi-Annual
2020-03-31	2020-06-25	0.13	1.47 %	Semi-Annual
2019-09-30	2019-11-29	0.12	73.71 %	Semi-Annual
2019-03-31	2019-06-26	13.00	87.32 %	Semi-Annual
2018-09-30	2018-11-30	0.12	1.55 %	Semi-Annual
2018-03-31	2018-06-27	0.12	1.50 %	Semi-Annual
2017-09-30	2017-11-30	0.12	1.76 %	Semi-Annual
2017-03-31	2017-06-26	0.12	110.23 %	Semi-Annual
		13.00	87.73 %	Semi-Annual
		0.12	1.43 %	Semi-Annual
		0.10	4.47 %	Semi-Annual
		2.52	0.85 %	Semi-Annual
		2.30	0.34 %	Semi-Annual
		2.45	22.90 %	Semi-Annual
		250.00	42.78 %	Semi-Annual
		250.00	21.39 %	Semi-Annual
		250.00	22.73 %	Annual
		250.00	0.96 %	Annual

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions